

# **Hepatitis-C Tracking Data Report**

(FY2018 Appropriation Act - Public Act 107 of 2017)

**March 1, 2018**

***Sec. 1878. By March 1 of the current fiscal year, the department shall provide a report to the senate and house appropriations subcommittees on the department budget, the senate and house fiscal agencies, the senate and house policy offices, and the state budget office on hepatitis C tracking data. At a minimum, the report shall include information on the following for individuals treated with Harvoni or any other treatment used to cure hepatitis C during the current fiscal year or a previous fiscal year:***

***(a) The total number of people treated broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.***

***(b) The total cost of treatment.***

***(c) The total cost of treatment broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.***

***(d) The cure rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.***

***(e) The reinfection rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.***



Michigan Department of  
Health & Human Services

RICK SNYDER, GOVERNOR  
NICK LYON, DIRECTOR

**Michigan Department of Health and Human Services  
Boilerplate Report  
2017 PA 107 Section 1878**

**(a) The total number of people treated broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.**

In Fiscal Year 2016-2017 a total of 1,074 people were treated through traditional Medicaid and 1,152 people were treated through the Healthy Michigan Plan for a grand total of 2,226 individuals.

**(b) The total cost of treatment.**

In Fiscal Year 2016-2017 a total of \$155,984,852 was spent on drugs designed to cure Chronic Hepatitis C.

**(c) The total cost of treatment broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.**

From the amount identified above, \$79,045,479 was spent on those treated through traditional Medicaid while \$76,939,373 was spent on those treated through the Healthy Michigan Plan.

**(d) The cure rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment & (e) The reinfection rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.**

In Fiscal Year 2015-2016<sup>i</sup>, the overall cure rate was 96.3% and the reinfection rate is 0.0%.

- Cure Rates
  - By Metavir Score<sup>ii</sup>
    - F4: 95.7%
    - F3: 97.8%
    - F2: 96.7%
    - F1: 100.0%
    - F0: 100.0%
  - By Genotype
    - 1a: 99.0%
    - 1b: 94.1%
    - 1 (subtype unknown): 97.9%
    - 2: 87.5%
    - 3: 95.7%
    - 4: 75.0%
  - By Medicaid Match Rate
    - Traditional Medicaid: 96.9%
    - HMP: 95.8%
    - Individuals who changed coverage between Traditional Medicaid and HMP: 100.0%
  - By Drugs Used During Treatment
    - Harvoni: 96.9%

- Sovaldi: 100.0%
- Combination of Daklinza and Sovaldi: 92.6%
- Reinfection Rates: 0.0% for all categories

---

<sup>i</sup> At this time, surveys detailing the cure and reinfection rates broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment for Fiscal Year 2016-2017 have not been returned to the department but will be published once available.

<sup>ii</sup> Those who had a Metavir score of F0 to F2 and received treatment included those who had other primary insurance coverage that covered the majority of the costs of treatment and those that had a co-morbidity, such as HIV or having received a transplant, which would necessitate additional consideration for treatment.